Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Blau Farmacêutica S.A. (BLAU3.SA)
Cotia, SP, BR
Blau Farmacêutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.27% | -8.09% | -8.75% | -3.07% | +6.65% | -5.51% | -0.49% | -30.75% | -64.55% | -64.38% | -64.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 7 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-3.0% Q1'26: +16.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-19.7% Q1'26: -66.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.0% Q1'26: -3.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.4% ★ Q1'26: +19.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+11.3% ★ Q1'26: +10.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+69.0% Q1'26: +27.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.52× Q1'26: 1.34× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 9 Rev. Ana. 5 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.37B
est: 1.38B (-0.6%)
|
1.41B
est: 1.51B (-6.9%)
|
1.37B
est: 1.57B (-12.8%)
|
1.75B
est: 1.75B (+0.4%)
|
1.70B
est: 1.73B (-1.7%)
|
1.97B
1.92B – 2.00B
+13.5% YoY
|
2.22B
2.11B – 2.29B
+12.7% YoY
|
2.52B
2.51B – 2.54B
+13.9% YoY
|
3.05B
2.97B – 3.10B
+20.8% YoY
|
| EBITDA |
530.17M
est: 443.77M (+19.5%)
|
523.28M
est: 487.51M (+7.3%)
|
405.23M
est: 478.19M (-15.3%)
|
406.15M
est: 530.60M (-23.5%)
|
394.08M
est: 525.75M (-25.0%)
|
596.66M
582.12M – 607.19M
+13.5% YoY
|
672.60M
642.10M – 694.67M
+12.7% YoY
|
766.27M
762.11M – 770.44M
+13.9% YoY
|
925.47M
902.91M – 941.79M
+20.8% YoY
|
| EBIT |
509.26M
est: 415.30M (+22.6%)
|
500.99M
est: 456.23M (+9.8%)
|
366.34M
est: 438.26M (-16.4%)
|
354.39M
est: 486.29M (-27.1%)
|
329.75M
est: 481.84M (-31.6%)
|
546.84M
533.51M – 556.49M
+13.5% YoY
|
616.44M
588.49M – 636.66M
+12.7% YoY
|
702.29M
698.47M – 706.10M
+13.9% YoY
|
848.19M
827.51M – 863.15M
+20.8% YoY
|
| Net Income |
325.22M
est: 355.14M (-8.4%)
|
363.37M
est: 381.51M (-4.8%)
|
249.81M
est: 366.48M (-31.8%)
|
217.21M
est: 282.67M (-23.2%)
|
294.96M
est: 357.96M (-17.6%)
|
384.02M
373.49M – 394.55M
+7.3% YoY
|
439.40M
394.21M – 484.59M
+14.4% YoY
|
456.39M
443.87M – 468.91M
+3.9% YoY
|
594.56M
575.72M – 608.18M
+30.3% YoY
|
| SGA |
201.77M
est: 202.28M (-0.3%)
|
174.94M
est: 222.22M (-21.3%)
|
226.88M
est: 241.87M (-6.2%)
|
283.52M
est: 268.37M (+5.6%)
|
287.66M
est: 265.92M (+8.2%)
|
301.79M
294.43M – 307.11M
+13.5% YoY
|
340.20M
324.77M – 351.36M
+12.7% YoY
|
387.58M
385.47M – 389.68M
+13.9% YoY
|
468.10M
456.69M – 476.35M
+20.8% YoY
|
| EPS |
1.81
est: 2.00 (-9.4%)
|
2.02
est: 2.15 (-5.9%)
|
1.41
est: 1.23 (+15.0%)
|
1.22
est: 0.96 (+26.7%)
|
0.98
est: 1.20 (-18.2%)
|
1.28
1.24 – 1.31
+7.3% YoY
|
1.42
1.31 – 1.61
+10.9% YoY
|
1.53
1.48 – 1.56
+7.2% YoY
|
1.98
1.92 – 2.03
+29.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck Brazil Small-Cap ETF BRF | 0.24% | 55.3K | 0.60% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.03% | 13.8K | 0.54% |
| 3 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.03% | 475.1K | 0.58% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 55.0K | 0.46% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 178.0K | 0.39% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 92.1K | 0.29% |
| 7 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 1.1K | 0.42% |
| 8 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 1.3K | 0.33% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 67.2K | 0.28% |
| 10 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 78.5K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amaro Arialdo de Souza Junior | Chief Business Unit Officer of Onco-Hematology and Specialties | — | male |
| Ana Luzia Marques Ivanov | Chief People, Management & ESG Officer | — | female |
| Douglas Leandro Rodrigues | Administrative, Financial & Investor Relations Director | — | male |
| Eliana Sueco Tibana Samano | Chief Medical Officer | — | female |
| Eliza Yukie Saito | Chief Quality Officer | — | female |
| Marcelo Rodolfo Hahn | Founder, Controller, Chief Executive Officer & Deputy Chairman | — | male |
| Milton Zanetti Rizo | Chief Industrial Operations Officer | — | male |
| Roberto Altieri | Chief Legal Officer | — | male |
| Roberto Carlos de Campos Morais | Chief M&A and Operations (USA and Europe) Officer & Director | — | male |
| Uilberson Carlos da Silva | Chief Research, Development & Innovation Officer | — | male |
| Vanderlei Schiavo | Chief Technology, Digital Transformation & Innovation Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BLAU3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
